<p>LncRNA <em>DLX6-AS1</em> promotes the proliferation, invasion, and migration of non-small cell lung cancer cells by targeting the <em>miR-27b-3p/GSPT1</em> axis</p>

Abstract

Background: Non-small cell lung cancer (NSCLC) has a significant impact on human health. The aim of this study was to explore the role of long non-coding RNA DLX6-AS1 in the proliferation, migration, and invasion of NSCLC cells. Methods: The expression of DLX6-AS1 in NSCLC tumor tissues and cell lines was examined by qRT-PCR. The effects of DLX6-AS1 knockdown on cell proliferation, migration, and invasion were assessed by Cell Counting Kit-8, wound healing, and transwell assays, respectively. Bioinformatics analyses, luciferase reporter assays, and RNA pull-down assays were employed to examine the mechanism by which DLX6-AS1 exerted its oncogenesis effects in NSCLC. The anti-tumor effect of silencing DLX6-AS1 in vivo was also evaluated. Results: DLX6-AS1 was over-expressed in NSCLC tumor tissues and cell lines and its level of expression was found to be associated with tumor size and advanced clinical stage in patients with NSCLC. Downregulation of DLX6-AS1 inhibited cell proliferation, cell clone formation, migration, and invasion of NSCLC cells. DLX6-AS1 was found to interact with miR-27b-3p / GSPT1. DLX6-AS1 expression was negatively correlated with miR-27b-3p expression, but positively correlated with GSPT1 expression in NSCLC samples. DLX6-AS1 knockdown also effectively suppressed tumor growth in an in vivo xenograft model. Conclusion: DLX6-AS1 regulated NSCLC progression by targeting the miR-27b-3p / GSPT1 axis, which may provide novel insights for NSCLC prognosis and therapy.

Integrated Analysis of lncRNA-miRNA-mRNA ceRNA Network Identified lncRNA EPB41L4A-AS1 as a Potential Biomarker in Non-small Cell Lung Cancer

“…Therefore, based on the ceRNA hypothesis, we further searched for the co-expressed mRNAs and miRNAs associated with lncRNA RP11-421L21.3 and finally discovered several miRNAs (miR-1, miR-128-3p, miR-150-5p, miR-27b-3p, and miR-613), which were correlated with the oncogenesis of NSCLC. Accumulating studies have demonstrated that these miRNAs were down-regulated in NSCLC tissues and could be participated in regulating the proliferation, invasion and metastasis of NSCLC cells through various pathways (Li J. et al, 2016;Chiu et al, 2017;Zheng et al, 2017;Jiang et al, 2018;Pan et al, 2018;Dai et al, 2019;Sun et al, 2019). However, there were no differences in expression levels of lncRNA RP11-390P2.4 and lncRNA RP11-421L21.3 between NSCLC tissues and adjacent non-cancerous tissues in our study.…”

“…According to the pathological classification, lung cancer can be classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) and approximately 80% of lung cancer cases are non-small cell lung cancer (NSCLC) (Siegel et al, 2019). Despite many improvements developed in diagnostic techniques and treatment strategies, the prognosis of NSCLC is still poor with a 5-year overall survival rate less than 20% (Ramalingam et al, 2011;Sun et al, 2019). As a majority of NSCLC patients are diagnosed at an advanced stage in a majority of patients, it may be the primary reason behind responding to the high mortality rate associated with this disease (Siegel et al, 2019).…”

<p>LncRNA LINC00665 Promotes Prostate Cancer Progression via miR-1224-5p/SND1 Axis</p>

“…Luciferase reporters were designed and reporter assay was performed as previously described. 20 The association between LINC00665 and miR-1224-5p or between miR-1224-5p and SND1 was tested by using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). In brief, 5000 DU-145 cells per well were seeded into 24-well plates and transfected with pmirGLO reporter (Promega) containing wild-type (wt) or mutant (mut) LINC00665 or SND1-3ʹ-UTR region and miR-1224-5p mimics using Lipofectamine 3000 reagent (Invitrogen).…”

The Search for Molecular Markers in a Gene-Orphan Case Study of a Pediatric Spinal Cord Pilocytic Astrocytoma

“…On the other hand, the predicted Lnc DLX6-AS1 mutation mapped within the intron 1 sequence and might affect the acceptor splicing site ctgcgagtgcgg (according to SplicePort: An Interactive Splice Site Analysis Tool, http://spliceport.cbcb.umd.edu/; Cutoff=0.643; Score=0.888). As recently documented, the expression of lnc DLX6-AS1 was related to important tumor features (26). Remarkably, DLX6-AS1 mRNA expression was detected within exosome vesicles, according to the repository exoRBase database (exorbase.org) of circular RNA (circRNA), long non-coding RNA (lncRNA) and messenger RNA (mRNA) derived from RNA-seq data analyses of human liquid biopsies derived exosomes.…”

“…The Proline insertion was localized in a Proline-rich region composed in humans by 9 residues, at N-terminus of the mature protein, not affecting Hox and Abdominal A superfamily functional domains. While DLX6 (Distal-Less Homeobox 6) gene was not involved in cancer, differently, lnc DLX6-AS1 was very recently deeply investigated, promoting tumorigenesis in pancreatic (35), colorectal (36), ovarian (37), lung (38), gastric (39) and liver (40) cancers. These contributions pointed for a role of this lncRNA in proliferation and metastasis induction and also suggested DLX6-AS1 as a potential therapeutic target (41).…”